Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

DENTSPLY International announces Lab Restructuring

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

UK Medical Device Testing Jumps 17%,...

Clinical investigations of medical devices in the UK reached...

Medtronic Secures FDA PMA for Infuse...

Medtronic announced that it has secured FDA premarket approval...

Medica Axon Diagnostics Merger Expands UK...

Teleradiology provider Medica Group has agreed to integrate Axon...

DENTSPLY International Inc., a global leader in professional dental products, today announced that it has reached agreement with the applicable works councils in Germany to proceed with restructuring portions of its laboratory business, consistent with its earlier announcement of September 17, 2014. The realignment of the lab business is designed to increase emphasis on innovative prosthetic materials while exiting portions of the lab equipment and fabrication businesses. The majority of this restructuring effort will be implemented during the remainder of fiscal 2015 and 2016.
The Company expects to incur total costs in the range of $33 to $38 million related to this initiative, the majority of which are expected to be recorded in the fiscal second quarter of 2015.  It is anticipated that approximately 85% of these costs will be cash outlays, including costs related to severance and employee related obligations.  This initiative impacts certain manufacturing operations from two sites in Germany, one of which will be closed and another that will be downsized.  The Company noted that this action is part of its broader efficiency program and the anticipated impact was included in the adjusted earnings guidance as previously provided (which excludes restructuring charges).

Latest stories

Related stories

UK Medical Device Testing Jumps 17%, AI and Neurotech Lead

Clinical investigations of medical devices in the UK reached...

Medtronic Secures FDA PMA for Infuse Bone Graft in TLIF

Medtronic announced that it has secured FDA premarket approval...

Medica Axon Diagnostics Merger Expands UK Clinical Reporting

Teleradiology provider Medica Group has agreed to integrate Axon...

Sutter Health Integrates AI Decision Support in Epic EHR

Sutter Health is integrating artificial intelligence-powered decision support technology...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »